Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.63 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151578 | 0.88 | SLC6A4 (0.78) | SLC6A4SLC6A3SLC6A2SOS1HTR2A | |
| SCHEMBL5697698 | 0.88 | SLC6A4 (0.78) | SLC6A4SLC6A3SLC6A2SOS1HTR2A | |
| SCHEMBL6947370 | 0.85 | SLC6A4 (0.73) | SLC6A4SLC6A3SLC6A2SOS1HTR2A | |
| SCHEMBL30682154 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL930692 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL15080486 | 0.84 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2HTR2AKCNH2 | |
| SCHEMBL7207923 | 0.83 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL7065556 | 0.82 | SLC6A4 (0.80) | SLC6A4SLC6A3SLC6A2SOS1HTR2A | |
| SCHEMBL6943295 | 0.82 | SLC6A4 (0.80) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL7066491 | 0.82 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2SOS1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | claimed |
| US-20050054688-A1 | Selective serotonin reuptake inhibitors in the treatment of disease | PFIZER INC | 2005-03-10 | — | — | US | claimed |
| WO-2005013984-A1 | SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR THE TREATMENT OF PREMATURE FEMALE ORGASM | PFIZER LIMITED (GB) | 2005-02-17 | — | — | WO | claimed |
| EP-1268396-A1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2003-01-02 | — | — | EP | claimed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | claimed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | claimed |
| WO-2001072687-A1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2001-10-04 | — | — | WO | claimed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4291239-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2023-12-20 | — | — | EP | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2004020414-A1 | OXYTOCIN INHIBITORS | PFIZER LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
| US-20030229001-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003064402-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| EP-1268396-A1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2003-01-02 | — | — | EP | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
| WO-2001072687-A1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054688-A1 | Selective serotonin reuptake inhibitors in the treatment of disease | HTR5A, HTR1A, HTR3B | SLC6A4 5/4885SLC6A3 21/4885SLC6A2 14/4885 |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885SLC6A3 784/4885SLC6A2 1349/4885 |
| US-20030229001-A1 | Treatment of male sexual dysfunction | OXTR, AVPR1B, AVPR2 | SLC6A4 168/4885SLC6A3 89/4885SLC6A2 106/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | SLC6A4 3731/4885SLC6A3 3775/4885SLC6A2 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.